Login to Your Account

Beta-arrrr, matey!

Synthetic antibody-based GPCR endocytosis inhibitor developed, study shows

By John Fox
Staff Writer

Thursday, October 5, 2017

A new Indian study showing that selectively targeting signal-regulating proteins with intrabodies provides a novel means of fine-tuning G protein-coupled receptor (GPCR) functions has important implications for new drug development.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription